Patent ID: 11965875
Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G | IPC C  G

Claim 8:
9. The method according to claim 6, wherein the step c) comprises: assessing the effect of the analyte on the phenotype of T cells in tumor tissue, assessing the effect of the analyte on the phenotype of dendritic cells in tumor tissue, assessing the effect of the analyte on the phenotype of macrophages in tumor tissue, and/or assessing the effect of the analyte on the phenotype of NK cells in tumor tissue;
wherein the phenotype of T cells comprises: a ratio of the T cells in tumor tissue, the proliferative capacity of the T cells, the activity of the T cells, the expression level of IL-2 in the T cells, the expression level of TNFα in the T cells, the expression level of granzyme in the T cells, the expression level of IFNγ in the T cells, and/or the expression level of PD1 in the T cells;
wherein the phenotype of dendritic cells comprises: a ratio of the dendritic cells in tumor tissue, the proliferative capacity of the dendritic cells, the activity of the dendritic cells, the expression level of co-stimulatory molecules CD80 and CD86 in the dendritic cells, and/or the expression level of PD-L1 in the dendritic cells;
wherein the phenotype of NK cells comprises: a ratio of the NK cells in tumor tissue, the proliferative capacity of the NK cells, the activity of the NK cells, the expression level of NKG2A in the NK cells, the expression level of granzyme in the NK cells, and/or the expression level of KIR in the NK cells;
wherein the phenotype of macrophages comprises: a ratio of the macrophages in tumor tissue, the proliferative capacity of the macrophages, the activity of the macrophages, and/or a ratio of M1-type macrophages to M2-type macrophages in tumor tissue.